Saltar al contenido
Merck
Todas las fotos(1)

Documentos

1200000

USP

Digoxin

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

12β-Hydroxydigitoxin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C41H64O14
Número de CAS:
20830-75-5
Peso molecular:
780.94
Beilstein:
77011
Número CE:
244-068-1
Número MDL:
MFCD00003674
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329749590
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

digoxin

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

Clave InChI

LTMHDMANZUZIPE-PUGKRICDSA-N

Información sobre el gen

human ... ATP1A1(476) , ATP1A2(477) , ATP1A3(478) , ATP1A4(480) , ATP1B1(481) , ATP1B2(482) , ATP1B3(483) , FXYD2(486)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Digoxin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Digoxin Tablets
  • Digoxin Injection
  • Digoxin Oral Solution

Acciones bioquímicas o fisiológicas

A cardiac glycoside, substrate for Pgp, upregulates Pgp expression and down regulates SXR (Steroid Xenobiotic Receptor).

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palabra de señalización

Danger

Frases de peligro

H300,H331,H373

Clasificaciones de peligro

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 7

1 of 7

Digoxin-21,21,22-d3 ≥95 atom % D, ≥90% (CP)

Sigma-Aldrich

901189

Digoxin-21,21,22-d3

Proscillaridin A phyproof® Reference Substance

PHL82774

Proscillaridin A

Digitoxin ≥92% (HPLC), powder

Sigma-Aldrich

D5878

Digitoxin

Digitoxin United States Pharmacopeia (USP) Reference Standard

USP

1199002

Digitoxin

Digoxigenin analytical standard

Supelco

D9026

Digoxigenin

Digitoxigenin

Sigma-Aldrich

D9404

Digitoxigenin

Digitonina, gran pureza CAS 11024-24-1 is a non-ionic detergent commonly used to solubilize membrane-bound proteins.

Millipore

300410

Digitonina, gran pureza

Robert J DiDomenico et al.
Pharmacotherapy, 34(11), 1121-1131 (2014-08-29)
To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5-0.9 ng/ml, by using a simplified nomogram to individualize digoxin dosing with standard dosing practices in patients with heart failure, and to characterize the relationship between
Roger W Jelliffe
Therapeutic drug monitoring, 34(4), 368-377 (2012-06-28)
Population pharmacokinetic and dynamic modeling is often employed to analyze data of steady-state trough serum digoxin concentrations in the course of what is frequently regarded as routine therapeutic drug monitoring (TDM). Such a monitoring protocol is extremely uninformative. It permits
Chang Gong et al.
Cancer research, 74(16), 4341-4352 (2014-07-02)
Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes
Mitesh Shah et al.
The American journal of cardiology, 114(3), 401-406 (2014-06-22)
Previous studies on digoxin use in patients with atrial fibrillation (AF) and the risk of all-cause mortality found conflicting results. We conducted a population-based, retrospective, cohort study of patients aged ≥65 years admitted to a hospital with a primary or secondary
Roger Soll et al.
The Cochrane database of systematic reviews, (1)(1), CD001080-CD001080 (2011-01-21)
Lendrum 1955 suggested that pulmonary edema secondary to congestive heart failure may contribute to neonatal respiratory distress syndrome (RDS). Based on this hypothesis, investigators began to use digitalis glycosides to improve myocardial contractility and decrease congestive heart failure. The first
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico